Grufity logoGrufity logo
StocksFundsSearch Filings

AbbVie Inc Stock Research

ABBV

137.56USD-1.06(-0.76%)Delayed

Market Summary

USD137.56-1.06
Delayed
-0.76%

ABBV Alerts

ABBV Stock Price

ABBV RSI Chart

ABBV Valuation

Market Cap

285.4B

Price/Earnings (Trailing)

24.12

Price/Sales (Trailing)

4.92

EV/EBITDA

19.96

Price/Free Cashflow

11.77

ABBV Price/Sales (Trailing)

ABBV Profitability

EBT Margin

23.21%

Return on Equity

68.6%

Return on Assets

8.53%

Free Cashflow Yield

8.49%

ABBV Fundamentals

ABBV Revenue

Revenue (TTM)

56.7B

Revenue Y/Y

-9.7%

Revenue Q/Q

-19.15%

ABBV Earnings

Earnings (TTM)

7.6B

Earnings Y/Y

-94.68%

Earnings Q/Q

-90.34%

Price Action

52 Week Range

132.74168.11
(Low)(High)

Last 7 days

-5.2%

Last 30 days

-15.0%

Last 90 days

-9.9%

Trailing 12 Months

-6.8%

ABBV Financial Health

Current Ratio

0.96

Debt/Equity

3.43

Debt/Cashflow

0.42

ABBV Investor Care

Dividend Yield

3.95%

Shares Dilution (1Y)

0.06%

Diluted EPS (TTM)

4.23

Peers (Alternatives to AbbVie)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
322.8B
1.6B
-3.71% 80.48%
-168.39
207.32
77.54% 1.62%
285.4B
56.7B
-14.98% -6.85%
24.12
4.92
0.03% -39.22%
87.6B
12.4B
-6.81% 6.09%
20.2
7.2
-25.07% -47.28%
85.0B
9.2B
2.07% 22.38%
26.07
9.23
15.86% 32.99%
23.4B
1.0B
-4.69% 49.89%
-21.96
22.55
22.88% -19.27%
11.8B
975.7M
3.71% 78.87%
-10.59
12.11
27.41% -212.78%
9.7B
2.0B
-8.21% -7.77%
13.31
4.89
12.05% 52.86%
MID-CAP
5.2B
-
-7.29% 316.43%
-16.55
2.5K
- -27.52%
3.5B
363.3M
17.72% 8.70%
-4.94
9.63
3.39% -55.81%
3.5B
204.6M
17.81% 4.32%
-6
17.05
-7.52% 10.65%
2.2B
18.9M
-10.74% -34.21%
-3.03
118.36
- -16.17%
SMALL-CAP
3.5B
-
0.59% -4.18%
-8.22
37.46
34.30% -67.22%
1.2B
256.5M
-28.21% 63.82%
12.26
4.75
66.85% 120.61%
315.4M
165.3M
-25.22% 48.69%
-3.45
1.91
130.70% 57.97%
41.8M
-
29.00% 3203.36%
-0.83
19.11
- -29.84%

Financials for AbbVie

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue-2.3%56,74158,05457,81957,34956,725
  S&GA Expenses-0.6%15,17215,26015,10314,88212,634
Costs and Expenses1.6%40,57339,93740,13039,95738,187
EBITDA13.0%16,80114,86817,558--
EBITDA Margin11.6%0.29*0.26*0.31*--
Earnings Before Taxes-33.0%9,02313,47714,78314,07114,051
EBT Margin-9.2%0.23*0.26*0.25*0.25*-
Interest Expenses-2,546----
Net Income-35.9%7,58511,83613,40712,63712,479
Net Income Margin-12.1%0.20*0.23*0.22*0.22*-
Free Cahsflow10.6%24,24821,92122,21422,047-
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-3.1%134,544138,805141,325143,186143,211
  Current Assets-6.9%26,48828,46330,36429,10026,509
    Cash Equivalents-27.1%6,7119,20111,8328,5216,098
  Inventory7.1%3,8333,5793,1723,3963,483
  Net PPE-0.1%4,9314,9354,8934,9585,075
  Goodwill0.2%32,22032,15631,72632,02832,298
  Current Liabilities-6.6%27,59029,53832,71234,47332,521
.    Short Term Borrowings0%1.001.0010.0017.0012.00
  Long Term Debt0.3%59,29259,13560,39961,00263,522
Shareholder's Equity-22.9%13,30317,25415,99414,68816,314
  Retained Earnings-50.0%2,3934,7844,9533,5165,103
  Additional Paid-In Capital1.9%19,61919,24519,05618,90618,731
Shares Outstanding0.1%1,7711,7701,771--
Minority Interest-12.1%29.0033.0033.0035.0031.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations-2.9%24,22824,94322,59022,92322,808
  Share Based Compensation1.0%678671668677729
Cashflow From Investing175.3%469-623-1,320-3,221-3,593
Cashflow From Financing3.1%-24,023-24,803-21,507-19,632-22,837
  Dividend Payments1.3%10,17810,0439,8519,6629,465
  Buy Backs32.6%1,9721,4871,6141,6161,617

Risks for ABBV

What is the probability of a big loss on ABBV?

69.6%


Probability that AbbVie stock will be more than 20% underwater in next one year

7.7%


Probability that AbbVie stock will be more than 30% underwater in next one year.

0%


Probability that AbbVie stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ABBV drawdown profile look like?

Y-axis is the maximum loss one would have experienced if AbbVie was unfortunately bought at previous high price.

Drawdowns

Returns for ABBV

Cumulative Returns on ABBV

16.2%


10-Year Cumulative Returns

16.5%


7-Year Cumulative Returns

11.0%


5-Year Cumulative Returns

19.2%


3-Year Cumulative Returns

What are the long-term rolling returns for ABBV?

FIve years rolling returns for AbbVie.

Annualized Returns

Which funds bought or sold ABBV recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-26
Fortis Group Advisors, LLC
new
-
281,210
281,210
0.09%
2023-05-26
SHEETS SMITH WEALTH MANAGEMENT
reduced
-0.46
-52,655
2,808,290
0.43%
2023-05-26
CYPRESS ASSET MANAGEMENT INC/TX
reduced
-0.13
-32,785
2,137,150
0.74%
2023-05-26
ProShare Advisors LLC
added
8.11
14,269,700
230,041,000
0.70%
2023-05-26
Cravens & Co Advisors, LLC
added
0.4
-10,305
1,032,080
0.96%
2023-05-25
Empower Advisory Group, LLC
new
-
77,659,900
77,659,900
0.35%
2023-05-25
Brandywine Global Investment Management, LLC
added
93.75
168,896,000
354,358,000
1.43%
2023-05-24
Old North State Trust, LLC
added
0.3
-15,000
1,312,000
0.91%
2023-05-23
Brookfield Corp /ON/
added
258
31,712,700
44,232,800
0.17%
2023-05-23
MOUNTAIN PACIFIC INVESTMENT ADVISERS INC/ID
reduced
-4.65
-186,701
2,938,490
0.21%

1–10 of 47

Latest Funds Activity

Are funds buying ABBV calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own ABBV
No. of Funds

AbbVie News

Nasdaq
Guru Fundamental Report for ABBV.
Nasdaq,
75 minutes ago
Zacks Investment Research
Yahoo Finance
10 Best June Dividend Stocks To Buy.
Yahoo Finance,
4 hours ago
StockNews.com
Yahoo Finance

Schedule 13G FIlings of AbbVie

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 16, 2023
blackrock inc.
7.8%
138,702,758
SC 13G/A
Feb 09, 2023
vanguard group inc
8.95%
158,317,552
SC 13G/A
Feb 09, 2022
vanguard group inc
8.28%
146,312,069
SC 13G/A
Feb 03, 2022
blackrock inc.
7.3%
128,197,555
SC 13G/A
Feb 16, 2021
capital research global investors
2.1%
37,921,062
SC 13G/A
Feb 10, 2021
vanguard group inc
8.08%
142,563,074
SC 13G/A
Jan 29, 2021
blackrock inc.
7.0%
124,423,484
SC 13G/A
Feb 14, 2020
capital research global investors
5.8%
86,602,693
SC 13G/A
Feb 12, 2020
vanguard group inc
8.28%
122,574,720
SC 13G/A
Feb 05, 2020
blackrock inc.
6.7%
98,593,810
SC 13G/A

ABBV Fair Value

Recent SEC filings of AbbVie

View All Filings
Date Filed Form Type Document
May 12, 2023
4
Insider Trading
May 10, 2023
8-K
Current Report
May 09, 2023
4
Insider Trading
May 09, 2023
4/A
Insider Trading
May 09, 2023
4
Insider Trading
May 09, 2023
4
Insider Trading
May 09, 2023
4
Insider Trading
May 09, 2023
4
Insider Trading
May 09, 2023
4
Insider Trading
May 09, 2023
4
Insider Trading

Latest Insider Trading transactions for ABBV

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-11
Strom Carrie C
sold (taxes)
-421,104
146
-2,876
svp & pres global allerg aesth
2023-05-05
BURNSIDE WILLIAM H.L.
acquired
-
-
1,450
-
2023-05-05
Alpern Robert J
acquired
-
-
1,450
-
2023-05-05
FREYMAN THOMAS C
acquired
-
-
1,450
-
2023-05-05
Roberts Rebecca B
acquired
-
-
1,450
-
2023-05-05
RAPP EDWARD J
acquired
-
-
1,450
-
2023-05-05
AUSTIN ROXANNE S
acquired
-
-
1,450
-
2023-05-05
Hart Brett J
acquired
-
-
1,450
-
2023-05-05
MEYER MELODY B
acquired
-
-
1,450
-
2023-05-05
TILTON GLENN F
acquired
-
-
1,450
-

1–10 of 50

Richard A. Gonzalez
50000
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

ABBV Income Statement

2023-03-31
Condensed Consolidated Statements of Earnings (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]  
Net revenues$ 12,225$ 13,538
Cost of products sold3,9864,052
Selling, general and administrative3,0393,127
Research and development2,2921,497
Acquired IPR&D and milestones150145
Other operating income(10)0
Total operating costs and expenses9,4578,821
Operating earnings2,7684,717
Interest expense, net454539
Net foreign exchange loss3525
Other expense (income), net1,804(776)
Earnings before income tax expense4754,929
Income tax expense234436
Net earnings2414,493
Net earnings attributable to noncontrolling interest23
Net earnings attributable to AbbVie Inc.$ 239$ 4,490
Per share data  
Basic earnings per share (in dollars per share)$ 0.13$ 2.52
Diluted earnings per share (in dollars per share)$ 0.13$ 2.51
Weighted-average basic shares outstanding (in shares)1,7701,771
Weighted-average diluted shares outstanding (in shares)1,7761,778

ABBV Balance Sheet

2023-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Current assets  
Cash and equivalents$ 6,711$ 9,201
Short-term investments1128
Accounts receivable, net11,47311,254
Inventories3,8333,579
Prepaid expenses and other4,4604,401
Total current assets26,48828,463
Investments257241
Property and equipment, net4,9314,935
Intangible assets, net64,84867,439
Goodwill32,22032,156
Other assets5,8005,571
Total assets134,544138,805
Current liabilities  
Short-term borrowings11
Current portion of long-term debt and finance lease obligations2,8004,135
Accounts payable and accrued liabilities24,78925,402
Total current liabilities27,59029,538
Long-term debt and finance lease obligations59,29259,135
Deferred income taxes2,1102,190
Other long-term liabilities32,24930,655
Commitments and contingencies
Stockholders' equity  
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,821,082,016 shares issued as of March 31, 2023 and 1,813,770,294 as of December 31, 20221818
Common stock held in treasury, at cost, 57,113,024 shares as of March 31, 2023 and 44,589,000 as of December 31, 2022(6,524)(4,594)
Additional paid-in capital19,61919,245
Retained earnings2,3934,784
Accumulated other comprehensive loss(2,232)(2,199)
Total stockholders' equity13,27417,254
Noncontrolling interest2933
Total equity13,30317,287
Total liabilities and equity$ 134,544$ 138,805